Causal Effect of Lipids and Lipoproteins on Atherosclerosis

Goldstein, 2015, A century of cholesterol and coronaries: from plaques to genes to statins, Cell, 161, 161, 10.1016/j.cell.2015.01.036

Skålén, 2002, Subendothelial retention of atherogenic lipoproteins in early atherosclerosis, Nature, 417, 750, 10.1038/nature00804

Chapman, 2010, Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors, Eur Heart J, 31, 149, 10.1093/eurheartj/ehp399

2012, Lipid-related markers and cardiovascular disease prediction, JAMA, 307, 2499

2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5

Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489

Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664

Lincoff, 2017, Evacetrapib and cardiovascular outcomes in high-risk vascular disease, N Engl J Med, 376, 1933, 10.1056/NEJMoa1609581

2017, Effects of anacetrapib in patients with atherosclerotic vascular disease, N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444

Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2

Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282

Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604

2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579

2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955

Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797

Davey Smith, 2014, Mendelian randomization: genetic anchors for causal inference in epidemiological studies, Hum Mol Genet, 23, R89, 10.1093/hmg/ddu328

Ference, 2015, Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps, Curr Opin Lipidol, 26, 566, 10.1097/MOL.0000000000000247

Ference, 2017, How to use Mendelian randomization to anticipate the results of randomized trials, Eur Heart J

2013, Discovery and refinement of loci associated with lipid levels, Nat Genet, 45, 1274, 10.1038/ng.2797

2015, A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease, Nat Genet, 47, 1121, 10.1038/ng.3396

Ference, 2012, Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis, J Am Coll Cardiol, 60, 2631, 10.1016/j.jacc.2012.09.017

Würtz, 2016, Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase, J Am Coll Cardiol, 67, 1200, 10.1016/j.jacc.2015.12.060

Ference, 2015, Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study, J Am Coll Cardiol, 65, 1552, 10.1016/j.jacc.2015.02.020

Ference, 2016, Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes, N Engl J Med, 375, 2144, 10.1056/NEJMoa1604304

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013

Ference, 2017, Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration, Eur Heart J, 10.1093/eurheartj/ehx450

Ference, 2017, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, Eur Heart J, 38, 2459, 10.1093/eurheartj/ehx144

Silverman, 2016, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis, JAMA, 316, 1289, 10.1001/jama.2016.13985

Thompson, 2008, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk, JAMA, 299, 2777, 10.1001/jama.299.23.2777

Johannsen, 2012, Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects, J Am Coll Cardiol, 60, 2041, 10.1016/j.jacc.2012.07.045

Ridker, 2009, Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study, Circ Cardiovasc Genet, 2, 26, 10.1161/CIRCGENETICS.108.817304

Ference, 2017, Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk, JAMA, 318, 947, 10.1001/jama.2017.11467

Hovingh, 2015, Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial, Lancet, 386, 452, 10.1016/S0140-6736(15)60158-1

Cannon, 2010, Safety of anacetrapib in patients with or at high risk for coronary heart disease, N Engl J Med, 363, 2406, 10.1056/NEJMoa1009744

Burgess, 2014, Using multivariable Mendelian randomization to disentangle the causal effects of lipid fractions, PLoS One, 9, e108891, 10.1371/journal.pone.0108891

White, 2016, Association of lipid fractions with risks for coronary artery disease and diabetes, JAMA Cardiol, 1, 692, 10.1001/jamacardio.2016.1884

Gaudet, 2015, Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia, N Engl J Med, 373, 438, 10.1056/NEJMoa1400283

Frikke-Schmidt, 2008, Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease, JAMA, 299, 2524, 10.1001/jama.299.21.2524

Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2

Holmes, 2015, Mendelian randomization of blood lipids for coronary heart disease, Eur Heart J, 36, 539, 10.1093/eurheartj/eht571

Andrews, 2017, Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study, Cardiovasc Diagn Ther, 7, 45, 10.21037/cdt.2017.01.01

Tardif, 2014, Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial, Eur Heart J, 35, 3277, 10.1093/eurheartj/ehu171

Nordestgaard, 2016, Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology, J Lipid Res, 57, 1953, 10.1194/jlr.R071233

2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063

Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604

Kamstrup, 2009, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 301, 2331, 10.1001/jama.2009.801

Emdin, 2016, Phenotypic characterization of genetically lowered human lipoprotein(a) levels, J Am Coll Cardiol, 68, 2761, 10.1016/j.jacc.2016.10.033